Análisis Argos
RPRX
RPRXBarata · ojo al riesgo1 señal de riesgo
Royalty Pharma plc · Healthcare
US$ 57.77
precio al 2026-07-04
Valor justo Argos*
US$ 71–83
vs. su valor justo
26% por debajo
Score Argos
49/100
Barata · ojo al riesgo
LA RESPUESTA
El mercado la precia para que se encoja 5.5% al año — menos de lo que viene demostrando (4.6%). Un negocio de calidad castigado por expectativas pesimistas: por eso está entre las llamadas de Argos. Ojo: tiene señales de riesgo en sus números — es barata con asterisco.
Recompensas
✓Cotiza por debajo de su valor justo: el mercado le pide menos crecimiento del que viene demostrando.
Riesgos
!Venta significativa de insiders en el último trimestre.
!Balance frágil: la deuda pesa sobre el negocio.
!Beneish M-Score sugiere manipulación (24.72)
VALOR4/6FUTURO4/6PASADO3/6SALUD1/6DIVIDENDO5/6
El Iris de calidad
VALOR4/6FUTURO4/6PASADO3/6SALUD1/6DIVIDENDO5/6
ValorCotiza por debajo de su valor justo
FuturoIngresos creciendo con fuerza
PasadoHistorial aceptable
SaludBalance frágil
DividendoDevuelve capital al accionista
Score Argos49de 100Barata · ojo al riesgo
Ingresos▲5%
US$ 2.4 B
Margen operativo▲15%
65.6%
Flujo de caja libre▼10%
US$ 2.5 B
Deuda neta
US$ 8.3 B
Lo esencial, sin ruido
Cap. de mercadoUS$ 24.8B
P/E32.2x
EV/EBITDA21.2x
FCF yield10%
ROIC10.5%
Margen operativo65.6%
Crecim. ingresos+5.1%/año
Piotroski F4/9
Competidores

Los rivales, con el mismo ojo

El Iris de calidad de cada competidor, lado a lado. Tocá uno para ver su análisis.

Novedades

Noticias recientes

etftrends.com · 11 jun
Healthcare ETFs: From Broad Exposure to Big Breakthroughs
With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sectors, supported by relatively steady demand regardless of the economic environment.
seekingalpha.com · 9 jun
Royalty Pharma plc (RPRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Royalty Pharma plc (RPRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
zacks.com · 9 jun
GSK to Strengthen Oncology Pipeline With $10.6B Nuvalent Buyout
GSK buys Nuvalent for $10.6 billion, adding three lung cancer pipeline candidates and expanding its precision oncology presence.
seekingalpha.com · 5 jun
Dividend Champion, Contender, And Challenger Highlights: Week Of June 7
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.
globenewswire.com · 4 jun
Royalty Pharma to present at the Goldman Sachs 47th Annual Global Healthcare Conference
NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026 at 4:00 p.m. ET.
seekingalpha.com · 19 may
Royalty Pharma plc (RPRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Royalty Pharma plc (RPRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
seekingalpha.com · 16 may
Royalty Pharma: Strong Execution, Expanding Pipeline And More Firepower Ahead
Portfolio Receipts increased 10% to $925 million, while Royalty Receipts grew 13% to $887 million. Q1 confirmed a supportive, broad-based momentum. Management's 2030 Portfolio Receipts target of $4.7 billion increasingly appears conservative. Recent funding agreements with Johnson & Johnson, alongside prior collaborations with Biogen, Merck, and Teva, strengthen Royalty Pharma's positioning. Capital flexibility and buybacks remain meaningful tailwinds. We remain buyers.
seekingalpha.com · 13 may
Royalty Pharma plc (RPRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Royalty Pharma plc (RPRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

* Valor justo Argos: estimación educativa del valor intrínseco según el propio flujo de caja de la empresa y su capacidad de crecimiento — no un precio objetivo ni una recomendación. Esto es información y educación, no asesoría de inversión. Rendimiento pasado no garantiza resultados futuros.